Also from this source


22 Jun, 2017, 15:52 ET AbbVie Declares Quarterly Dividend

You just read:

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma

News provided by

AbbVie

19 Jan, 2017, 07:00 ET